Diana Borenshtein is a distinguished expert in the field of health and life sciences, currently serving as the Vice President at Kanda Software. With a Ph.D. in Molecular and Systems Toxicology from MIT, Diana has dedicated over two decades to advancing medical research and development. Her career includes significant roles such as Clinical Applications Manager and Cell and Gene Therapy Specialist at Miltenyi Biotec, where she honed her expertise in gene therapy and drug discovery.Diana is an active participant in the academic and professional community, contributing to the MIT Sloan Artificial Intelligence in Pharma and Biotech online program. Her work primarily focuses on innovative therapies and technologies that promise to revolutionize patient care and treatment outcomes. Based in the United States, Diana maintains a robust presence on social media platforms like Facebook and LinkedIn, where she shares insights and engages with both peers and followers.Her commitment to her field is evident in her proactive approach to research and her involvement in cutting-edge projects that address critical challenges in healthcare. Diana's leadership at Kanda Software is poised to influence significant advancements in health sciences, leveraging her deep knowledge and extensive experience to drive success in her new role starting January 2024.